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In previous studies, it has been shown that recombinant human neuregulin-1(rhNRG-1) is capable 24 of improving the survival rate in animal models of doxorubicin (DOX)-induced cardiomyopathy; 25 however, the underlying mechanism of this phenomenon remains unknown. In this study, the role of 26 rhNRG-1 in attenuating doxorubicin-induce apoptosis is confirmed. Neonatal rat ventricular 27 myocytes (NRVMs) were subjected to various treatments, in order to both induce apoptosis and 28 determine the effects of rhNRG-1 on the process. Activation of apoptosis was determined by 29 observing increases in the protein levels of classic apoptosis markers (including cleaved caspase-3, benefit is limited by its cardiotoxicity (Singal et al., 1998; Swain et al., 2003) . cardiomyopathy is characterized by irreversible left ventricular dysfunction and congestive heart failure 49 with a poor prognosis (Bristow et al., 1978; Takemura et al., 2007) . Nevertheless, to date, researchers 50 and scientists have attempted a variety of approaches aimed at preventing the deleterious action of 51 doxorubicin, but presently the ability of these treatments to protect the heart from damage remains 52 limited (Takemura et al., 2007) . Dexrazoxane is the only well established and clinically approved 53 cardioprotectant against ANT cardiotoxicity (Popelova et al., 2009; Sterba et al., 2013) . Therefore, the 54 development of more therapies which may be used to prevent and/or treat the cardiotoxicity of 55 doxorubicin remains a critical issue in both cardiology and oncology. Neuregulin (NRG)-1, a member of the neuregulin family, is expressed in many cell types and organs, 58 including the heart. Neuregulin-1/erbB signaling is essential for embryonic cardiac development.
59
Post-natal conditional erbB2-deficiency in cardiomyocytes may result in severe cardiomyopathy and 60 enhanced myocyte susceptibility for DOX-induced death (Crone et al., 2002; Ozcelik et al., 2002 However, the underlying molecular mechanism has yet to be defined. Akt is known to regulate many 85-23, revised 1996) . In 104 brief, the hearts were washed, the atria removed and the ventricles minced after dissection in 105 HEPES-buffered saline solution containing 130 mM NaCl, 3 mM KCl, 1 mM NaH 2 PO 4 , 4 mM glucose, 106 and 20 mM HEPES (the pH of which was adjusted to 7.35 with NaOH). The tissues were dispersed in a 107 series of incubations at 37 °C in HEPES-buffered saline solution containing 1.2 mg ml−1 pancreatin and 108 0.14 mg ml−1 collagenase (Worthington, NJ, USA). After centrifugation, the cells were resuspended in a 109 DMEM/F-12 medium (GIBCO, Grand Island, NY, USA) containing 5% (vol/vol) heat-inactivated horse 110 6 serum, 0.1 mM ascorbate, insulin-transferring sodium selenite media supplement, 100 U ml−1 penicillin, 111 100 μg ml−1 streptomycin, and 0.1 mM bromodeoxyuridine. The dissociated cells were preplated at 112 37 °C for 1 h, then diluted to 1 × 106 cells ml−1 and, plated in culture dishes coated with 10 μg ml− All analyses were performed using SPSS software (v13.0, Chicago, IL, USA). 
Effects of rhNRG-1 on phospho-Akt in NRVMs
172
Akt is known to have an inhibitory effect on apoptosis in several cell types (Matsui et al., 2001) . In order 173 to determine the effects of rhNRG-1 on Akt phosphorylation in NRVMs, phospho-Akt (for serine 473) 174 was detected (Fig. 2) . Western blotting analysis showed that DOX downregulated the levels of 175 phospho-Akt in NRVMs, but these levels were restored to the above basal levels in cells pretreated with 176 9 rhNRG-1. In order to determine whether or not the restoration of Akt phophorylation by rhNRG-1 is 177 involved in the signaling of PI3K, the effect of its specific inhibitor LY294002 was used. apoptosis was detected by a fivefold increase in the number of TUNEL-positive myocytes (Fig. 3A, B) 186 and the western blotting analysis of ration of Bcl-2/Bax (Fig. 3C ). Decreased cell viability was 187 determined via MTT assay (Fig. 3D ). Therefore, it was shown that the PI3K/Akt signaling pathway is 188 indeed involved in the anti-apoptotic effect of rhNRG-1. In conclusion, the present study strongly demonstrated that rhNRG-1 protects NRVM from DOX-induced 260 apoptosis, and that rhNRG-1 may potentially be used to treat DOX-induced cardiotoxicity. 
